A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy ...

Scott B. Sellinger, MD, FACS, discusses the challenges facing urologists, the loss of telehealth flexibility, and why bipartisan action remains urgent.

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure. In this video, Sean P. Collins, MD, PhD, a radiation oncologist at Tampa General Hospital in Tampa ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...

This announcement follows positive topline data from a phase 1b/2a clinical trial of EG110A in patients with NDO following spinal cord injury.

Bladder Cancer | Clinical | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...